摘要
多发性骨髓瘤（MM）是一种浆细胞恶性增殖性肿瘤,目前仍是一种不可治愈的恶性血液病,几乎所有的MM患者最终都会复发、耐药.随着对MM发病及耐药机制的不断研究,新型药物如免疫调节剂、蛋白酶体抑制剂、单克隆抗体、组蛋白去乙酰化酶抑制剂、热休克蛋白抑制剂的应用,极大地延长了复发难治性MM（RRMM）患者的总生存及无进展生存时间.文章主要对国内外新型靶向药物研究进展作一综述.
Multiple myeloma （MM）, a malignant tumor of plasma cell proliferation, is still an incurable malignant hematological disease. Most of the MM patients will eventually end up with relapse and drug resistance. With the continuous study of pathogenesis and the mechanism of drug resistance of MM, the application of new drugs such as immune modulators, proteasome inhibitors, monoclonal antibodies, histone inhibitors, heat shock protein inhibitors, has greatly improved the overall survival and progression free time in patients with relapsed and refractory myeloma. This article mainly discusses the progress of new targeted drugs at home and abroad.
作者
李诗雅
马艳萍
Li Shiya Ma Yatoping(Department of Hematology, the Second Hospital of Shanxi Medical University, Taiyuan 030001, China)
出处
《白血病．淋巴瘤》
CAS
2017年第7期436-440,共5页
Journal of Leukemia & Lymphoma
关键词
多发性骨髓瘤
复发
难治
靶向治疗
Multiple myeloma
Relapse
Refractory
Targeted therapy
